Roy AN - Search Results

1

Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study.

Khelif A, Saleh MN, Salama A, Portella MDSO, Duh MS, Ivanova J, Grotzinger K, Roy AN, Bussel JB. Khelif A, et al. Among authors: roy an. Am J Hematol. 2019 Feb;94(2):200-208. doi: 10.1002/ajh.25348. Epub 2018 Nov 29. Am J Hematol. 2019. PMID: 30417939 Free PMC article.

2

Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study.

Peffault de Latour R, Huynh L, Ivanova JI, Totev T, Bilginsoy M, Antin J, Roy A, Duh MS. Peffault de Latour R, et al. Ann Hematol. 2020 Apr;99(4):743-752. doi: 10.1007/s00277-019-03809-5. Epub 2020 Feb 17. Ann Hematol. 2020. PMID: 32065291

3

Grainger JD, Blanchette VS, Grotzinger KM, Roy A, Bussel JB. Grainger JD, et al. Br J Haematol. 2019 Apr;185(1):102-106. doi: 10.1111/bjh.15732. Epub 2018 Dec 27. Br J Haematol. 2019. PMID: 30592022 Free article.

4

Value of transfusion independence in severe aplastic anemia from patients' perspectives - a discrete choice experiment.

Pickard AS, Huynh L, Ivanova JI, Totev T, Graham S, Mühlbacher AC, Roy A, Duh MS. Pickard AS, et al. J Patient Rep Outcomes. 2017;2(1):13. doi: 10.1186/s41687-018-0032-y. Epub 2018 Mar 1. J Patient Rep Outcomes. 2017. PMID: 29757294 Free PMC article.

5

The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.

Tremblay G, Dolph M, Roy AN, Said Q, Forsythe A. Tremblay G, et al. Among authors: roy an. Clin Ther. 2020 May;42(5):860-872.e8. doi: 10.1016/j.clinthera.2020.02.020. Epub 2020 Mar 18. Clin Ther. 2020. PMID: 32199608

6

Thrombopoietin receptor agonist discontinuation rates and reasons among patients with immune thrombocytopenia: a study of administrative claims linked with medical chart review.

Cuker A, Lal L, Roy A, Elliott C, Carlyle M, Martin C, Haenig J, Viana R. Cuker A, et al. Ann Hematol. 2022 Sep;101(9):1915-1924. doi: 10.1007/s00277-022-04888-7. Epub 2022 Jul 18. Ann Hematol. 2022. PMID: 35849155

7

A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists.

Dolph M, Roy A, Bhor M, Hearnden J, Kwon CS, Forsythe A, Tremblay G, Briggs A. Dolph M, et al. J Comp Eff Res. 2018 Aug;7(8):775-784. doi: 10.2217/cer-2018-0034. Epub 2018 May 31. J Comp Eff Res. 2018. PMID: 29848048 Free article.

8

Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel.

Cooper N, Hill QA, Grainger J, Westwood JP, Bradbury C, Provan D, Thachil J, Ramscar N, Roy A. Cooper N, et al. Acta Haematol. 2021;144(4):418-426. doi: 10.1159/000510676. Epub 2021 Mar 31. Acta Haematol. 2021. PMID: 33789275 Free PMC article.

9

Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists.

Forsythe A, Schneider J, Pham T, Bhor M, Said Q, Allepuz A, Socorro O Portella MD, Kwon CS, Roy AN. Forsythe A, et al. Among authors: roy an. J Comp Eff Res. 2020 May;9(7):447-457. doi: 10.2217/cer-2019-0177. Epub 2020 Mar 16. J Comp Eff Res. 2020. PMID: 32175766 Free article.

10

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia.

Tremblay G, Dolph M, Bhor M, Said Q, Roy A, Elliott B, Briggs A. Tremblay G, et al. Clinicoecon Outcomes Res. 2018 Nov 5;10:715-721. doi: 10.2147/CEOR.S177338. eCollection 2018. Clinicoecon Outcomes Res. 2018. PMID: 30464564 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters